News mRNA ‘wake-up call’ shows promise as universal cancer vaccin... Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint inhibitor immunotherapy, significantly boosted anti-tumour activit
Partner Content Partner Content Strategic Competitive Intelligence and the role of the Micro... Immuno-Oncology Conference - London - September
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
